We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Study: Little Evidence That Priority Review Voucher Program Spurs Drug Development
Study: Little Evidence That Priority Review Voucher Program Spurs Drug Development
Despite its lucrative promise, the FDA’s priority review voucher program has done little to spur development of novel treatments for tropical and rare pediatric diseases, a new study in JAMA concludes.